Barriers and new opportunities in developing effective therapies for diabetic neuropathy: International expert consensus recommendations

被引：0

作者：

Brock, C. ^{[1
,2
,3
]}

Andersen, H. ^{[4
]}

Alibegovic, A. C. ^{[5
]}

Andersen, S. T. ^{[6
]}

Andreasen, L. J. ^{[7
]}

Charles, M. H. ^{[8
]}

Christensen, D. H. ^{[6
,9
]}

Drewes, A. M. ^{[1
,2
,3
]}

Gall, M. -a ^{[5
]}

Gylfadottir, S. S. ^{[4
,10
]}

Hansen, C. S. ^{[11
]}

Hecquet, S. K. ^{[11
]}

Jensen, T. S. ^{[10
]}

Karlsson, P. ^{[10
,12
]}

Knudsen, L. B. ^{[13
]}

Lobato, C. B. ^{[14
,15
]}

Kufaishi, H. ^{[11
]}

Maalmi, H. ^{[16
]}

Mizrak, H., I ^{[11
]}

Nilsen, K. B. ^{[17
]}

Perkins, B. A. ^{[18
]}

Roikjer, J. ^{[1
,2
]}

Rossing, P. ^{[19
,20
]}

Rungby, J. ^{[19
,20
]}

Romer, J. ^{[5
]}

Stouge, A. ^{[4
]}

Sulek, K. ^{[19
,20
]}

Softeland, E. ^{[21
]}

Tahrani, A. A. ^{[5
,22
]}

Terkelsen, A. J. ^{[4
,11
]}

Tesfaye, S. ^{[23
,24
]}

Wegeberg, A. ^{[3
]}

Akerstrom, T. ^{[6
,7
]}

Brock, B. ^{[22
,26
]}

Pop-Busui, R. ^{[25
]}

机构：

[1] Aalborg Univ, Dept Clin Med, Aalborg, Denmark

[2] Aalborg Univ Hosp, Steno Diabet Ctr North Denmark, Aalborg, Denmark

[3] Aalborg Univ Hosp, Dept Gastroenterol & Hepatol, Mech Sense, Aalborg, Denmark

[4] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark

[5] Novo Nord A S, Clin Dev & Project Leadership, Soborg, Denmark

[6] Aarhus Univ Hosp, Dept Endocrinol & Internal Med, Aarhus, Denmark

[7] Novo Nord A S, Diabet Pharmacol, Soborg, Denmark

[8] Steno Diabet Ctr Aarhus, Aarhus, Denmark

[9] Aarhus Univ Hosp, Dept Clin Epidemiol Dept, Aarhus, Denmark

[10] Aarhus Univ, Danish Pain Res Ctr, Dept Clin Med, Aarhus, Denmark

[11] Steno Diabet Ctr Copenhagen, Complicat Res, Herlev, Denmark

[12] Aarhus Univ, Core Ctr Mol Morphol, Dept Clin Med, Sect Stereol & Microscopy, Aarhus, Denmark

[13] Novo Nord A S, Chief Sci Advisor Off, Res & Early Dev, Copenhagen, Denmark

[14] Copenhagen Univ Hosp Amager & Hvidovre, Sect Endocrinol, Dept Med, DK-2650 Hvidovre, Denmark

[15] Univ Copenhagen, Fac Hlth & Med Sci, Dept Biomed Sci, Copenhagen, Denmark

[16] Heinrich Heine Univ Dusseldorf, Inst Clin Diabetol, German Diabet Ctr, Leibniz Ctr Diabet Res, Dusseldorf, Germany

[17] Oslo Univ Hosp, Dept Neurol, Sect Clin Neurophysiol, Oslo, Norway

[18] Univ Toronto, Dept Med, Div Endocrinol & Metab, Toronto, ON, Canada

[19] Steno Diabet Ctr Copenhagen, Herlev, Denmark

[20] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark

[21] Univ Bergen, Haukeland Univ Hosp, Bergen, Norway

[22] Univ Birmingham, Dept Metab & Syst Sci, Birmingham, England

[23] Sheffield Teaching Hosp, Diabet Res Unit, Sheffield, England

[24] Univ Sheffield, Sheffield, England

[25] Oregon Hlth & Sci Univ, Dept Med, Div Endocrinol Diabet & Clin Nutr, Portland, OR 97239 USA

[26] Aalborg Univ Hosp, Selma Lagerlofsvej 249, Gistrup, Denmark

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2025年 / 221卷

关键词：

Diabetic neuropathy; Drug development; Optimized design and outcomes; Painful neuropathy; Consensus; CARDIOVASCULAR AUTONOMIC NEUROPATHY; PERIPHERAL NEUROPATHY; MICHIGAN NEUROPATHY; SCREENING INSTRUMENT; RISK-FACTORS; COMPLICATIONS TRIAL/EPIDEMIOLOGY; NERVE-CONDUCTION; PAIN; POLYNEUROPATHY; POPULATION;

D O I：

10.1016/j.diabres.2025.112010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Diabetic neuropathy (DN) affects up to half of individuals with type 1 and type 2 diabetes. Despite evidence that improving metabolic and cardiovascular health can slow its progression, DN remains a significant clinical challenge due to the lack of disease-modifying therapies and effective pain management strategies. This consensus aimed to identify gaps and recommend strategies to address these challenges. Method: A workshop, initiated by Steno Diabetes Centre Copenhagen and the Danish Diabetes and Endocrinology Academy, conducted a gap analysis based on insights from clinical studies, observational cohorts, and clinical practice. Online invitations targeted experienced clinicians, researchers, and drug developers committed to improving DN treatment through innovative clinical trials. Thirty-five participants from six countries reached consensus via a Delphi process on key steps to advance DN therapy. Result: Four critical barriers and needs were addressed: (1) Translating bench research to clinical practice, (2) Enhancing clinical trial design, (3) Improving outcome measures, and (4) Identifying effective treatments for painful DN. Conclusion: Successful interventional trials require robust outcome measures to capture clinically meaningful changes in DN phenotypes, providing the basis for developing effective, disease-modifying treatments.

引用

页数：10

共 93 条

[1] Validity and reliability of the Turkish version of the Michigan Neuropathy Screening Instrument [J].

Aktar Reyhanioglu, Duygu ;

Adiyaman, Suleyman Cem ;

Bektas, Murat ;

Bulut, Onur ;

Ozgen Saydam, Basak ;

Bayraktar, Firat ;

Kara, Bilge .

TURKISH JOURNAL OF MEDICAL SCIENCES, 2020, 50 (04) :789-797

[2] Correlation of Retinal Nerve Fiber Layer Thickness and Visual Fields in Glaucoma: A Broken Stick Model [J].

Alasil, Tarek ;

Wang, Kaidi ;

Yu, Fei ;

Field, Matthew G. ;

Lee, Hang ;

Baniasadi, Neda ;

de Boer, Johannes F. ;

Coleman, Anne L. ;

Chen, Teresa C. .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 157 (05) :953-959

[3]

American Diabetes Association, 2022, Clin Diabetes, V40, P10, DOI 10.2337/cd22-as01

[4] Risk Factors for Incident Diabetic Polyneuropathy in a Cohort With Screen-Detected Type 2 Diabetes Followed for 13 Years: ADDITION-Denmark [J].

Andersen, Signe T. ;

Witte, Daniel R. ;

Dalsgaard, Else-Marie ;

Andersen, Henning ;

Nawroth, Peter ;

Fleming, Thomas ;

Jensen, Troels M. ;

Finnerup, Nanna B. ;

Jensen, Troels S. ;

Lauritzen, Torsten ;

Feldman, Eva L. ;

Callaghan, Brian C. ;

Charles, Morten .

DIABETES CARE, 2018, 41 (05) :1068-1075

[5]

[Anonymous], 2019, DIABETES CARE, V42, pS1, DOI [10.2337/dc20-Sint, 10.2337/dc19-SINT01, 10.2337/dc16-S001, 10.2337/dc19-Sint01, 10.2337/dc20-SINT]

[6]

[Anonymous], 2008, Clin Diabetes, DOI [10.2337/diaclin.26.2.77, DOI 10.2337/DIACLIN.26.2.77]

[7] Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials [J].

Apperloo, Ellen M. ;

Neuen, Brendon L. ;

Fletcher, Robert A. ;

Jongs, Niels ;

Anker, Stefan D. ;

Bhatt, Deepak L. ;

Butler, Javed ;

Cherney, David Z., I ;

Herrington, William G. ;

Inzucchi, Silvio E. ;

Jardine, Meg J. ;

Liu, Chih-Chin ;

Mahaffey, Kenneth W. ;

McGuire, Darren K. ;

McMurray, John J., V ;

Neal, Bruce ;

Packer, Milton ;

Perkovic, Vlado ;

Sabatine, Marc S. ;

Solomon, Scott D. ;

Staplin, Natalie ;

Szarek, Michael ;

Vaduganathan, Muthiah ;

Wanner, Christoph ;

Wheeler, David C. ;

Wiviott, Stephen D. ;

Zannad, Faiez ;

Heerspink, Hiddo J. L. .

LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08) :545-557

[8]

Arshad AR, 2016, JCPSP-J COLL PHYSICI, V26, P374, DOI 2318

[9] Prevalence and Determinants of Painful and Painless Neuropathy in Type 1 Diabetes Mellitus [J].

Barbosa, Margarida ;

Saavedra, Ana ;

Oliveira, Sofia ;

Reis, Ligia ;

Rodrigues, Filipa ;

Severo, Milton ;

Sittl, Reinhard ;

Maier, Christoph ;

Carvalho, Davide M. .

FRONTIERS IN ENDOCRINOLOGY, 2019, 10

[10] Validation and Reliability of the Portuguese Version of the Michigan Neuropathy Screening Instrument [J].

Barbosa, Margarida ;

Saavedra, Ana ;

Severo, Milton ;

Maier, Christoph ;

Carvalho, Davide .

PAIN PRACTICE, 2017, 17 (04) :514-521

← 1 2 3 4 5 6 7 8 9 10 →